BofA raised the firm’s price target on Cellebrite (CLBT) to $25 from $24 and keeps a Buy rating on the shares. The firm fine tunes its estimates to reflect positive underlying trends following the company’s Q3 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target raised to $24 from $23 at JPMorgan
- Cellebrite DI: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Cellebrite DI Positioned for Growth: Buy Rating Affirmed Amid Federal Demand Recovery and Strategic Alignments
- Cellebrite Reports Strong Q3 2025 Financial Results
- Closing Bell Movers: Cisco jumps 7% to record highs after beat-and-raise